[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0400231A2 - Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények - Google Patents

Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények

Info

Publication number
HUP0400231A2
HUP0400231A2 HU0400231A HUP0400231A HUP0400231A2 HU P0400231 A2 HUP0400231 A2 HU P0400231A2 HU 0400231 A HU0400231 A HU 0400231A HU P0400231 A HUP0400231 A HU P0400231A HU P0400231 A2 HUP0400231 A2 HU P0400231A2
Authority
HU
Hungary
Prior art keywords
immune
deception
cancer
treatment
methods
Prior art date
Application number
HU0400231A
Other languages
English (en)
Inventor
Yoram Reiter
Avital Lev
Original Assignee
Technion Research And Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd. filed Critical Technion Research And Development Foundation Ltd.
Publication of HUP0400231A2 publication Critical patent/HUP0400231A2/hu
Publication of HUP0400231A3 publication Critical patent/HUP0400231A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát egy olyan immunmolekula képezi, mely tartalmaz egyoldható humán I. osztályú MHC effektordomént és az említett oldhatóhumán I. osztályú MHC effektordoménhez kapcsolt célzódomént. Atalálmány továbbá az immunmolekulát kódoló nukleinsavszerkezetekre, azimmunmolekula előállítási eljárására és a molekulát tartalmazókészítményekre vonatkozik. A találmány további tárgya az immunmolekulaalkalmazása egy adott célsejt, különősen rákos sejtek elpusztítására. Ó
HU0400231A 2001-06-19 2002-06-18 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer HUP0400231A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29891501P 2001-06-19 2001-06-19
US10/108,511 US20030017134A1 (en) 2001-06-19 2002-03-29 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
PCT/IL2002/000478 WO2002102299A2 (en) 2001-06-19 2002-06-18 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
HUP0400231A2 true HUP0400231A2 (hu) 2005-05-30
HUP0400231A3 HUP0400231A3 (en) 2010-11-29

Family

ID=26805971

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400231A HUP0400231A3 (en) 2001-06-19 2002-06-18 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer

Country Status (11)

Country Link
US (1) US20030017134A1 (hu)
EP (1) EP1409547B1 (hu)
JP (1) JP5148804B2 (hu)
CA (1) CA2451353C (hu)
CZ (1) CZ200479A3 (hu)
DK (1) DK1409547T3 (hu)
ES (1) ES2652017T3 (hu)
HU (1) HUP0400231A3 (hu)
NZ (2) NZ581793A (hu)
PL (1) PL373302A1 (hu)
WO (1) WO2002102299A2 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2404489A1 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US8022190B2 (en) * 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
US8202841B2 (en) 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
EP2371850A3 (en) 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US7977457B2 (en) * 2006-05-19 2011-07-12 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
CN102459298A (zh) * 2009-05-05 2012-05-16 阿尔特姆恩科技责任有限公司 化学可编程免疫
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
MX354663B (es) * 2011-06-22 2018-03-14 Hoffmann La Roche Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i.
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
BR112015011111A2 (pt) * 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
WO2014096015A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
ES2820729T3 (es) * 2013-02-15 2021-04-22 Univ Johns Hopkins Redirectores de células T específicas de antígenos
CN106132428B (zh) * 2014-01-21 2021-08-06 阿尔伯特爱因斯坦医学院 用于快速和全面t细胞免疫监测的细胞平台
EP3458096A4 (en) 2016-05-18 2019-11-27 Cue Biopharma, Inc. T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
AU2017273147B2 (en) 2016-06-02 2024-06-13 Immunocore Limited Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein
CN116970060A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2020514375A (ja) 2017-03-15 2020-05-21 キュー バイオファーマ， インコーポレイテッド 免疫応答を調節するための方法
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019162937A1 (en) * 2018-02-20 2019-08-29 Technion Research & Development Foundation Limited Immunotherapeutic composition for the treatment of cancer
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
EP0889964A1 (en) * 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6140113A (en) * 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US6235445B1 (en) * 1998-04-15 2001-05-22 Fuji Photo Film Co., Ltd. Thermal transfer sheet
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
CA2404489A1 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
AU2001255326B2 (en) * 2000-04-12 2005-12-15 University Of Rochester Targeted vaccine delivery systems
WO2001090198A1 (en) * 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy

Also Published As

Publication number Publication date
CZ200479A3 (cs) 2004-11-10
NZ581793A (en) 2010-07-30
NZ530656A (en) 2007-05-31
EP1409547A2 (en) 2004-04-21
CA2451353A1 (en) 2002-12-27
ES2652017T3 (es) 2018-01-31
EP1409547B1 (en) 2017-09-20
JP2005506058A (ja) 2005-03-03
CA2451353C (en) 2012-01-17
HUP0400231A3 (en) 2010-11-29
WO2002102299A3 (en) 2003-11-27
US20030017134A1 (en) 2003-01-23
DK1409547T3 (en) 2018-01-08
JP5148804B2 (ja) 2013-02-20
WO2002102299A2 (en) 2002-12-27
EP1409547A4 (en) 2007-05-02
PL373302A1 (en) 2005-08-22

Similar Documents

Publication Publication Date Title
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
ATE354957T1 (de) Durch trans-spaltung erhaltene therapeutische molekule
HUP0302352A2 (hu) SN-38 lipid komplexek és alkalmazásuk
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
HUP0400659A2 (hu) Kitinázokkal, kitinázszerű molekulákkal és gyulladásos megbetegedéssel kapcsolatos eljárások, készítmények és reagenskészletek
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
AU2001259353A1 (en) Novel mutated form of arginine deiminase
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1108266T1 (el) Παραγωγα διβενζο(c) χρωμεν-6-ονης ως αντικαρκινικοι παραγοντες
GR3033253T3 (en) Tri(platinum) complexes
DK0689586T3 (da) VPR-funktion og -aktivitet
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
ATE514718T1 (de) Peptabody für krebsbehandlung
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished